Sort
261,768 grants matching “gene therapy”
MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency
$897,699Ward Peterson · Mitorainbow Therapeutics, Inc. · R44 · FY2023 · GM
CVD in American Indians Study and Data Management Center and OK Field Center
$897,599Julie A Stoner · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2017 · HL
CVD in American Indians Study and Data Management Center and OK Field Center
$897,599Julie A Stoner · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2016 · HL
CELL BIOLOGY OF MYCOBACTERIUM AVIUM INFECTION
$897,530University Of California San Francisco · P01 · FY2001 · AI
Interdepartmental Biotechnology Training Program
$897,517Karl D Wittrup · Massachusetts Institute Of Technology · T32 · FY2007 · GM
Research Project 2
$897,403Eric Vallabh Minikel · Broad Institute, Inc. · U19 · FY2024 · NS
Augmenting immunity via HER2-targeted immunotherapy and PSK M.Disis/L.Standish
$897,391Leanna J Standish · Bastyr University · U19 · FY2011 · AT
Gene Therapy for LCA5-Assocated Inherited Retinal Degeneration: Extension to Pediatric Cohorts
$897,359Tomas S Aleman · University Of Pennsylvania · R01 · FY2025 · FD
Matching panels of in vivo and in vitro model system of pediatric brain tumors
$897,346Xiaonan Li · Lurie Children'S Hospital Of Chicago · U01 · FY2020 · CA
Mechanisms of fibrosis in post-surgical lymphedema
$897,335Babak J Mehrara · Sloan-Kettering Inst Can Research · R01 · FY2020 · HL
Mechanisms of fibrosis in post-surgical lymphedema
$897,335Babak J Mehrara · Sloan-Kettering Inst Can Research · R01 · FY2021 · HL
Mechanisms of fibrosis in post-surgical lymphedema
$897,335Babak J Mehrara · Sloan-Kettering Inst Can Research · R01 · FY2019 · HL
Identification of Lethal Melanomas at the Time of Diagnosis
$897,329Nancy E Thomas · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Impact of environmental metal/metalloid exposures on mammographic breast density, a marker of breast cancer
$897,129Marybeth Martin · Georgetown University · U01 · FY2017 · ES
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes
$897,025Jian-Min Yuan · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Mechanisms of Therapy and Model Development in Viral Hepatitis and Liver Diseases
$897,021T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
Exonuclease Epigenetic Sequencing
$896,993Eric Ervin · Electronic Biosciences, Inc. · R44 · FY2020 · HG
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
$896,990Farhad Parhami · Max Biopharma, Inc. · R44 · FY2023 · DK
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
$896,878Anthony D Saleh · Mirecule, Inc. · R44 · FY2025 · CA
Identification of human tumor-associated antigens
$896,832Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Analysis of cancer-related immune suppressor mechanisms in mice
$896,773Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
$896,761Min Lu · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2012 · AI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
$896,700John F Dipersio · Washington University · R35 · FY2022 · CA
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease
$896,654Mark T Dransfield · University Of Alabama At Birmingham · UH3 · FY2021 · TR
Rare Disease Translational Research
$896,627Ewy Mathã · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR